| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C Neill Epperson, Zenab Amin, Frederick Naftolin, Angela Cappiello, Kathryn A Czarkowski, Stephanie Stiklus, George M Anderson, John H Krysta. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. Journal of psychopharmacology (Oxford, England). vol 21. issue 4. 2007-08-24. PMID:16891341. |
while preliminary, the results suggest that serotonin may be less critical to the pathogenesis of depression during the menopause. |
2007-08-24 |
2023-08-12 |
human |
| Janne Grønli, Eldbjørg Fiske, Robert Murison, Bjørn Bjorvatn, Eli Sørensen, Reidun Ursin, Chiara M Porta. Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression. Behavioural brain research. vol 181. issue 1. 2007-08-24. PMID:17477980. |
one of the most established hypotheses of depression focuses on alteration of the serotonergic (5-ht) function. |
2007-08-24 |
2023-08-12 |
rat |
| Janne Grønli, Eldbjørg Fiske, Robert Murison, Bjørn Bjorvatn, Eli Sørensen, Reidun Ursin, Chiara M Porta. Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression. Behavioural brain research. vol 181. issue 1. 2007-08-24. PMID:17477980. |
hence, the present paper reports a study on simultaneously measurement of hippocampal levels of serotonin and gaba during waking and sleep in the chronic mild stress (cms) animal model of depression. |
2007-08-24 |
2023-08-12 |
rat |
| Markus Jokela, Katri Räikkönen, Terho Lehtimäki, Riikka Rontu, Liisa Keltikangas-Järvine. Tryptophan hydroxylase 1 gene (TPH1) moderates the influence of social support on depressive symptoms in adults. Journal of affective disorders. vol 100. issue 1-3. 2007-08-23. PMID:17134762. |
tryptophan hydroxylases (tphs) are involved in the biosynthesis of serotonin and are therefore candidate genes for psychiatric disorders, including depression. |
2007-08-23 |
2023-08-12 |
Not clear |
| G Haja. [Dual acting reuptake inhibitors in the treatment of depression and pain]. Deutsche medizinische Wochenschrift (1946). vol 131 Suppl 8. 2007-08-23. PMID:17139587. |
two neurotransmitters, serotonin and noradrenaline, play an important role not only in the pathophysiology of depression but importantly also as mediators in pain regulation. |
2007-08-23 |
2023-08-12 |
Not clear |
| P Chipman, A F Jorm, M Prior, A Sanson, D Smart, X Tan, S Eastea. No interaction between the serotonin transporter polymorphism (5-HTTLPR) and childhood adversity or recent stressful life events on symptoms of depression: results from two community surveys. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 144B. issue 4. 2007-08-14. PMID:17450557. |
no interaction between the serotonin transporter polymorphism (5-httlpr) and childhood adversity or recent stressful life events on symptoms of depression: results from two community surveys. |
2007-08-14 |
2023-08-12 |
human |
| Murray B Stein, Christopher Ron Cantrell, Michael C Sokol, Michael T Eaddy, Manan B Sha. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric services (Washington, D.C.). vol 57. issue 5. 2007-08-09. PMID:16675762. |
this study evaluated adherence with selective serotonin reuptake inhibitors (ssris) or serotonin-norepinephrine reuptake inhibitors (snris) among patients who newly initiated therapy for anxiety with or without comorbid depression; the study also quantified the health-related economic consequences of nonadherence. |
2007-08-09 |
2023-08-12 |
Not clear |
| Wei Ni, Stephanie W Watt. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clinical and experimental pharmacology & physiology. vol 33. issue 7. 2007-08-09. PMID:16789923. |
the function of the serotonin transporter (sert) is to take up and release serotonin (5-hydroxytyptamine (5-ht)) from cells and this function of sert in the central nervous system (cns) is well-documented; sert is the target of selective serotonin reuptake inhibitors used in the treatment of cns disorders, such as depression. |
2007-08-09 |
2023-08-12 |
mouse |
| Xin Wang, Olga Dergacheva, Harriet Kamendi, Christopher Gorini, David Mendelowit. 5-Hydroxytryptamine 1A/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function. Hypertension (Dallas, Tex. : 1979). vol 50. issue 2. 2007-08-08. PMID:17576856. |
the 5-hydroxytryptamine 1a/7 receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin increased respiratory frequency by itself and also prevented the fentanyl-induced respiratory depression. |
2007-08-08 |
2023-08-12 |
Not clear |
| Xin Wang, Olga Dergacheva, Harriet Kamendi, Christopher Gorini, David Mendelowit. 5-Hydroxytryptamine 1A/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function. Hypertension (Dallas, Tex. : 1979). vol 50. issue 2. 2007-08-08. PMID:17576856. |
the 5-hydroxytryptamine 4alpha agonist bimu-8 did not by itself change inspiratory activity but prevented the mu-opioid-mediated respiratory depression. |
2007-08-08 |
2023-08-12 |
Not clear |
| Xin Wang, Olga Dergacheva, Harriet Kamendi, Christopher Gorini, David Mendelowit. 5-Hydroxytryptamine 1A/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function. Hypertension (Dallas, Tex. : 1979). vol 50. issue 2. 2007-08-08. PMID:17576856. |
these results suggest that activation of 5-hydroxytryptamine receptors, particularly 5-hydroxytryptamine 4alpha agonists, may be a useful therapeutic approach in preventing opioid-evoked cardiorespiratory depression. |
2007-08-08 |
2023-08-12 |
Not clear |
| Michael Bauer, Hans-Jürgen Möller, Edith Schneide. Duloxetine: a new selective and dual-acting antidepressant. Expert opinion on pharmacotherapy. vol 7. issue 4. 2007-08-07. PMID:16503814. |
antidepressants that inhibit the re-uptake of serotonin and noradrenaline might offer a chance to reduce the multiple symptoms of depression, as both serotonin and noradrenaline seem to be responsible for the emotional and physical symptoms of depression. |
2007-08-07 |
2023-08-12 |
Not clear |
| Michael Bauer, Hans-Jürgen Möller, Edith Schneide. Duloxetine: a new selective and dual-acting antidepressant. Expert opinion on pharmacotherapy. vol 7. issue 4. 2007-08-07. PMID:16503814. |
duloxetine, a novel dual acting, selective serotonin and noradrenaline-re-uptake inhibitor, has demonstrated high remission rates and good efficacy on physical symptoms, especially painful physical symptoms of depression. |
2007-08-07 |
2023-08-12 |
Not clear |
| L A W Jans, W J Riedel, C R Markus, A Bloklan. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Molecular psychiatry. vol 12. issue 6. 2007-08-07. PMID:17160067. |
a model is proposed in which a combination of various factors that may compromise 5-ht functioning in one person can result in depression or other 5-ht-related pathology. |
2007-08-07 |
2023-08-12 |
human |
| R O'Hara, C M Schröder, R Mahadevan, A F Schatzberg, S Lindley, S Fox, M Weiner, H C Kraemer, A Noda, X Lin, H L Gray, J F Hallmaye. Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Molecular psychiatry. vol 12. issue 6. 2007-08-07. PMID:17353910. |
the s allele variant of the serotonin transporter gene (5-htt) has recently been observed to moderate the relationship of stress to depression and anxiety. |
2007-08-07 |
2023-08-12 |
human |
| Kim M Smits, Luc J M Smits, Jan S A G Schouten, Frenk P M L Peeters, Martin H Prin. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clinical therapeutics. vol 29. issue 4. 2007-08-07. PMID:17617292. |
does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? |
2007-08-07 |
2023-08-12 |
Not clear |
| Kim M Smits, Luc J M Smits, Jan S A G Schouten, Frenk P M L Peeters, Martin H Prin. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clinical therapeutics. vol 29. issue 4. 2007-08-07. PMID:17617292. |
an estimated 30% to 40% of patients with depression do not sufficiently respond to treatment with selective serotonin reuptake inhibitors (ssris) and the period in which treatment efficacy can be assessed is relatively long. |
2007-08-07 |
2023-08-12 |
Not clear |
| P C Chandler-Laney, E Castaneda, C E Pritchett, M L Smith, M Giddings, A I Artiga, M M Boggian. A history of caloric restriction induces neurochemical and behavioral changes in rats consistent with models of depression. Pharmacology, biochemistry, and behavior. vol 87. issue 1. 2007-08-06. PMID:17490740. |
hcr coupled with intermittent but not daily access to pf exaggerated rats' anorectic response to fluoxetine (p<0.05); was associated with a significant 71% and 58% reduction of 5-ht and dopamine, respectively, in the medial prefrontal cortex; and induced behaviors consistent with models of depression. |
2007-08-06 |
2023-08-12 |
rat |
| Cornelius Schüle, Thomas C Baghai, Daniela Eser, Susanne Hecht, Igor Hermisson, Christoph Born, Sibylle Häfner, Caroline Nothdurfter, Rainer Rupprech. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 2. 2007-08-01. PMID:17455104. |
there is preliminary evidence that the atypical antipsychotic aripiprazole, which is a partial agonist at d(2) and 5-ht(1a) receptors and a potent antagonist at 5-ht(2a) receptors, may be useful as an augmentation strategy in treatment-resistant depression. |
2007-08-01 |
2023-08-12 |
Not clear |
| Michael Kluge, Petra Schüssler, Axel Steige. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 8. 2007-07-30. PMID:17337164. |
sleep studies in patients with major depression receiving the new selective norepinephrine and serotonin reuptake inhibitor (snri) duloxetine are lacking. |
2007-07-30 |
2023-08-12 |
human |